GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Institutional Ownership

AIM ImmunoTech (STU:HXB2) Institutional Ownership : 6.78% (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AIM ImmunoTech's institutional ownership is 6.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AIM ImmunoTech's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AIM ImmunoTech's Float Percentage Of Total Shares Outstanding is 96.79%.


AIM ImmunoTech Institutional Ownership Historical Data

The historical data trend for AIM ImmunoTech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Institutional Ownership Chart

AIM ImmunoTech Historical Data

The historical data trend for AIM ImmunoTech can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 9.84 9.84 9.84 9.70 7.10 7.09 7.08 7.04 6.86 6.78

AIM ImmunoTech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines